sitagliptin
AssetAlso DW6012, MK0431, MK-0431, Sitagliptin phosphate
Dipeptidyl peptidase-4 (DPP-4) inhibitor increasing active incretin hormone levels
- Stage
- Approved
- Modality
- Small molecule
- Target
- Insulin/IGF-1 signalling
- 11
- Indications
- 247
- Trials
- 3
- Developers
Indications
11Diabetes mellitus
Approved, ema.europa.eu, 7 Oct 2026
Type 2 diabetes
Approved, accessdata.fda.gov, 7 Oct 2026
Chronic renal insufficiency
Phase 3, Completed, NCT00509262, clinicaltrials.gov, 7 Oct 2026
8 more
In the full profile
- Targets and what it contains2
- Owner and partners3
- Trials247
- Evidence for its targets3
- Competitors12
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 7 Oct 2026, 24 sources